Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07132463) titled 'Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study' on Aug. 12.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Fudan University

Condition: Rectal Cancer

Intervention: Radiation: Long-course chemoradiotherapy Drug: Tislelizumab combined with the CAPOX regimen

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: August 2025

Target Sample Size: 154

To know more...